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SUMMARY
The benets and challenges of incorporating biomarkers into the development of anti-
cancer agents have been increasingly discussed. In many cases, a sensitive subpopulation
of patients is determined based on pre-clinical data and/or by retrospectively analyzing
clinical trial data. Prospective exploration of sensitive subpopulations of patients may
enable us to eciently develop denitively eective treatments, resulting in accelerated
drug development and a reduction in development costs. We consider the development of
a new molecular-targeted treatment in cancer patients. Given preliminary but promising
ecacy data observed in a phase I study, it may be worth designing a phase II clinical
trial that aims to identify a sensitive subpopulation. In order to achieve this goal, we
propose a Bayesian randomized phase II clinical trial design incorporating a biomarker
that is measured on a graded scale. We compare two Bayesian methods, one based on
subgroup analysis and the other on a regression model, to analyze a time-to-event end-
point such as progression-free survival (PFS) time. The two methods basically estimate
Bayesian posterior probabilities of PFS hazard ratios in biomarker subgroups. Exten-
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sive simulation studies evaluate these methods' operating characteristics, including the
correct identication probabilities of the desired subpopulation under a wide range of
clinical scenarios. We also examine the impact of subgroup population proportions on
the methods' operating characteristics. Although both methods' performance depends
on the distribution of treatment eect and the population proportions across patient
subgroups, the regression-based method shows more favorable operating characteristics.
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1. INTRODUCTION
Recently, the benets and challenges of incorporating biomarkers into the development
of anti-cancer agents have been increasingly discussed [1]. Many clinical trials are con-
ducted to develop new molecular-targeted anticancer agents that are likely to benet
only a subset of patients. If a clinical trial is performed in a broad population of pa-
tients, which includes insensitive as well as sensitive patients, any eect of a new agent
on the sensitive subset of patients may be missed. Therefore, drug development should
aim to optimize the target population of patients for treatment by appropriately focus-
ing on patients who could obtain a sucient benet from a molecular-targeted agent.
In addition, identifying the sensitive subset of patients may be a vital process in clin-
ical development in terms of speeding up the drug development process and reducing
development costs [2, 3, 4, 5].
The following two examples of clinical development represent two dierent extremes
in the approach to this problem. First, trastuzumab, which is a humanized monoclonal
antibody with high specicity for the human epidermal growth factor receptor 2 (HER2)
protein, demonstrated high anti-tumor activity in patients with HER2-overexpressing
metastatic breast cancer [6, 7, 8]. Based on preclinical and clinical data that strongly
supported the existence of a sensitive subpopulation of patients, the clinical development
of trastuzumab prospectively focused on studying the agent in HER2-overexpressing
breast cancer patients. Secondly, during the development of monoclonal antibodies tar-
geting epidermal growth factor receptor (EGFR), such as panitumumab, and EGFR
tyrosine kinase inhibitors (TKIs), such as getinib, patients were enrolled in clinical
trials without preselection based on EGFR status or other biomarkers [6, 7]. For exam-
ple, Amado et al. [9] retrospectively analyzed whether the eect of panitumumab on
progression-free survival (PFS) in patients with metastatic colorectal cancer diered by
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KRAS status and showed a signicant treatment eect in the wild-type KRAS subgroup.
That is, in the rst case, solid prior data enabled clinical investigators to prospectively
design subsequent clinical trials to develop a molecular-targeted agent in a patient sub-
population identiable with a biomarker assay. In the other case, retrospective subgroup
analysis of a phase III trial conducted in unselected patients was able to successfully iden-
tify a sensitive patient subpopulation. In many cases, however, the reality may lie in
between these two cases.
If a study population of patients contains non-sensitive subpopulations, a much larger
sample size would be required to establish statistically signicant results in a nal conr-
matory phase III trial [10]. When considering the entire course of a new agent's clinical
development, therefore, conducting a properly designed phase II trial may be key to
raising the \success probability" of a subsequent phase III trial. In particular, pharma-
cogenetically developed drugs often rely on assays to measure target expression levels
(e.g., HER2 or EGFR) on a graded scale; these levels are then dichotomized to dene
two subsets of patients with positive or negative status. We call the subset of patients
with positive status the sensitive subpopulation. In this paper, we consider identifying
the sensitive subpopulation using a graded-scale biomarker in a randomized phase II
clinical trial to develop a new molecular-targeted agent. In order to design the phase
II trial, we adopt a Bayesian approach for the decision-making exibility it aords dur-
ing the exploratory phase of clinical development. We compare two Bayesian methods,
one based on subgroup analysis and the other on a regression model, in terms of their
performance in identifying a sensitive subpopulation. In addition, we consider interim
analyses to prematurely terminate the trial due to futility.
As reviewed by Yin [11], there is a substantial literature on study designs that are
used to identify sensitive patient subpopulations, including Jiang et al. [10], Wang et
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al. [12], Brannath et al. [13], Eickho et al. [14], and Jenkins et al. [15] proposed
adaptive two-stage designs in which the patient subset(s) specied in the rst stage is
used to evaluate the treatment eect in the second stage. Their proposed study designs
presume that two mutually exclusive patient subgroups are determined in advance on
the basis of preclinical research or a separate exploratory study. Our focus is simply on
identifying a sensitive patient subpopulation in the phase II stage, although the above
study designs consider phase II/III or phase III trial settings.
This paper is organized as follows. In Section 2, we provide a motivating example.
Section 3 outlines the study design of a Bayesian randomized phase II clinical trial to
identify a sensitive patient subpopulation. We conduct extensive simulation studies to
examine the operating characteristics of our proposed study design in Section 4. We
close with a brief discussion in Section 5.
2. A MOTIVATING EXAMPLE
In this section, we present a case study based on the actual clinical development of a
new molecular-targeted monoclonal antibody. Pre-clinical and clinical works suggested
that anti-tumor activity of the new antibody should depend signicantly on the target
protein amounts. In this study the intensity of the biomarker expression is dened using
a graded scale (e.g., 0, 1+, 2+, 3+), with higher values indicating higher expression.
Results from a phase I dose-nding clinical trial suggested a possible association between
biomarker expression and the ecacy of the antibody, that is, longer PFS time tended
to be observed in patients with higher expression (e.g., 2+ and 3+). In this study, we
assume monotonicity in the ecacy of the new agent with respect to the biomarker
grade.
While eective rst-line therapies exist for patients with advanced stages of cancer
and poor prognoses, in particular hepatocellular carcinoma (HCC) and pancreatic car-
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cinoma, no standard second-line treatments have yet been established. In randomized
phase II clinical trials to develop second-line oncology treatments, the experimental and
control arms (arms E and C) should be \best supportive case (BSC) + new agent" and
\BSC + placebo", and a time-to-event outcome such as PFS time is often used as the
primary endpoint [16]. In some cases, a biomarker may not only be a predictive factor
for a new agent but also a prognostic factor for patients with a specic cancer type. In
this study, we assume that the biomarker predicts the ecacy of the new agent, but does
not predict patient prognosis. That is, we consider the situation where the ecacy in
the control (placebo) arm is not modied by the biomarker. However, it is not dicult
to extend our proposed study design to cases where prognosis diers between subgroups.
Under these settings, we consider designing a randomized phase II trial to assess
whether the addition of a new monoclonal antibody therapy to BSC suciently benets
the patients in terms of prolongation of PFS time. The biomarker grade is used as a
stratication factor when randomization is carried out. In order to summarize the PFS
data, we basically use a hazard ratio comparing arm E to arm C, which is denoted by .
In this study, we consider evaluating the hazard ratios in G biomarker subgroups, which
are denoted by g, g = 1; : : : ; G. Our specic goal is to nd the upper subset consisting
of subgroups g  0, which meets the denition of the sensitive subpopulation, by
evaluating these hazard ratios. Then, a subsequent phase III trial is to be conducted in
the identied subpopulation. The value of cuto 0 2 f1; : : : ; G + 1g is unknown and
will be determined based on data observed in the trial. As one of the two extreme cases,
0 = 1 suggests that arm E should be benecial for the entire population of patients,
and one can make a decision to proceed to a subsequent phase III trial that enrolls the
entire population of patients. On the other hand, the cuto 0 = G + 1 indicates that
arm E will not be benecial for any subgroup and the \no-go" decision to a subsequent
6
phase III trial should be taken.
3. BIOMARKER-BASED BAYESIAN RANDOMIZED PHASE II STUDY DESIGN
We use the two Bayesian methods that are both based on a common probability model
for PFS time. One method is based on a subgroup analysis (S-A method), and the other
on a regression model (R-M method).
3.1 Notation, probability model for PFS time, and Bayesian posterior computation
For patient i, let xi denote the treatment indicator, with xi = 1 if patient i receives
the experimental arm and xi = 0 if they receive the control arm. Let Ti denote PFS
time for patient i. For subgroups 1 to G dened by the biomarker grade, zi;g = 1
if patient i is in subgroup g and 0 if not. Thus, zi =(zi;1; : : : ; zi;G) is the subgroup
indicator vector for patient i. Let 1; : : : ; G denote the proportions of patients in
subgroups 1; : : : ; G, who would be enrolled into the phase II trial. These proportions
reect the true biomarker subgroup prevalence in the entire population of patients.
Although  = (1; : : : ; G) is actually unknown, in the simulation study we will handle
the proportions  as xed values and vary the values to examine the sensitivity of
simulation results to the subgroup prevalence. That is, although the proportions 
could be handled as additional parameters to be estimated in a Bayesian study design,
we will not consider them in this study.
The two Bayesian methods explained in the next subsection commonly use the fol-
lowing proportional hazards model. Under the proportional hazards assumption in each
subgroup, the hazard at time t for patient i with xi can be modeled as




where h0(t) denotes the baseline hazard function and g denotes the regression coecient
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for xi in subgroup g. According to Sinha et al. [17] and Ibrahim et al. [18], we use the
partial likelihood of the Cox proportional hazards model as the likelihood to compute the
posterior distributions of the parameters in the two Bayesian methods. We used Markov
chain Monte Carlo (MCMC) to compute the posteriors [19], because the joint posterior
distribution of regression coecient parameters is not readily available in closed form.
As the criteria to identify the sensitive subpopulation, we basically use the following
Bayesian posterior probability given the observed data D from the trial,
p( <  j D) >  (2)
where  is the upper limit and  is the upper probability cuto. These design param-
eters,  and , need to be calibrated on the basis of operating characteristics of the
study design, which are examined in simulation studies. More specically, let Dg denote
the data observed in subgroup g and Dall denote the data observed in all G subgroups.
3.2 Two Bayesian methods to analyze PFS time
The objective of the phase II trial is to prove the concept of a targeted therapy, that
is, to evaluate whether higher ecacy of the new antibody is observed in patients with
higher biomarker expression. Therefore we assume the monotonicity in the ecacy of
the new antibody in both methods but in dierent ways.
The S-A method separately evaluates the hazard ratio in each subgroup using the
data observed in that subgroup. Assuming the monotonic increase in p(g < 
 j Dg)
for g = 1; : : : ; G, this method sequentially assesses whether p(g < 
 j Dg) >  from
subgroup 1 to G. That is, if p(1 < 
 j D1) is higher than , we determine 0 = 1. If
not, we proceed to subgroup 2. If p(2 < 
 j D2) > , we determine 0 = 2 and decide
to identify subgroups 2 to G as the sensitive subpopulations. Similar computations and
decision making are then repeated up to subgroup G. If all of the posterior probabilities,
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p(1 < 
 j D1), : : :, p(G <  j DG) are lower than , we determine 0 = G + 1. We
assume a non-informative normal prior N(0,1000) for each of the regression coecient
parameters, 1; : : : ; G, to perform these posterior computations.
The R-M method assumes a monotonic decrease in hazard ratio for the biomarker
subgroups with the parameter constraint 1 > 2 > : : : > G. In addition, this method
uses the data observed in all G subgroups, Dall , to evaluate the posterior distribution of
g for g = 1; : : : ; G. For computational convenience, we reparameterize (1; : : : ; G) with
(1; 1; : : : ; G 1) as 1 = 1, 2 = 1 1, : : :, G = G 1 G 1 = 1 1 2 : : : G 1,
where 1 > 0; 2 > 0; : : : ; G 1 > 0. Assuming a non-informative normal prior N(0,1000)
for 1 and a non-informative gamma prior Ga(0.001,0.001) with mean 1 and variance
1000 for 1; : : : ; G 1, we compute the marginal posterior distribution of the hazard
ratios. Based on the computations, we nd the cuto 0 to satisfy the following equation,
0 = inf
g2(1;:::;G)
fg j p(g <  j Dall) > g : (3)
That is, the cuto 0 is specied as the minimum of the integers g 2 f1; : : : ; Gg that
meet p(g < 
 j Dall) > .
Although we suppose the S-A method to have more exibility, it may perform more
poorly at identifying a sensitive subpopulation due to its subgroup-analysis approach.
In contrast, although we expect the R-M method to show a higher performance owing
to the parameter constraint and the use of Dall , this method may be vulnerable to
departures from the monotonicity assumption. We will evaluate the advantages and
disadvantages of the two methods in the simulation study.
3.3 Interim study monitoring rules
It may be important to terminate a clinical trial early from ethical and practical points
of view. In the randomized phase II trial, we consider early termination of the entire trial
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due to futility by planning interim analyses. Although it may also be useful to consider
partly terminating insensitive patient subgroups or reducing the size of those subgroups,
we did not take these measures in this study. This is because it may be generally desirable
to obtain sucient data on patients in the non-selected subpopulation in order to more
precisely evaluate their response to and the safety of the new treatment [20].
The number and timing of interim analyses should be determined by taking into
account the practicalities of patient enrollment rates and collecting and processing of
study data. In the randomized phase II trial, we consider two interim analyses with
the rst and second analyses occurring after 60% and 80% of patients are recruited,
respectively. When using the S-A method, given the lower probability cuto stop, we
consider the experimental arm to have disappointingly insucient ecacy if p(g < 
 j
Dg) < stop for all g. Similarly, we stop the trial early if p(g <  j Dall) < stop for
all g when using the R-M method. The lower cuto stop needs to be calibrated on the
basis of the study design operating characteristics in the same way as the upper cuto
. As another interim monitoring rule, it may be useful to include early stopping for
ecacy by using an ecacy stopping criterion, such as p(g < 
 j D) > stop;Eff . Due
to the same reasons mentioned above, however, we will not apply this rule to the phase
II trial.
4. EVALUATION OF OPERATING CHARACTERISTICS
4.1 Parameter calibration and simulation plan
To evaluate and compare the two Bayesian methods in the case study with four sub-
groups, we simulated the trial 5,000 times using extensively varying situations. We used
MCMC methods to obtain samples from the posterior distributions of the parameters.
In order to complete the study design, we needed to calibrate the design parameters
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(; ; stop; N) on the basis of the desired type I error rate under a null hypothesis and
power under an alternative hypothesis in the trial with the projected total sample size
N . The detailed denitions of type I error and power are given below.
We rst performed a series of simulation studies with all 12 combinations of the
three xed upper limits ( = .70, .80, .85), the two upper probability cutos ( = .70,
.80), and the two lower probability cutos (stop = .10, .20) under N = 500. Although
the total sample size of 500 may be too large for a phase II trial, we used N= 500
to reliably evaluate the performances of the two methods in the simulation study. The
simulation results are summarized in Supplemental Tables (see the supplementary on-line
materials). After determining the best combination of , , and stop, we evaluated the
operating characteristics using six sample size values (N = 250, 300, 350, 400, 450, 500)
to determine the appropriate sample size for the randomized phase II trial. Furthermore,
we assumed the ve patterns of subpopulation proportions  = (1; 2; 3; 4), as shown
in Table 1, to evaluate the sensitivity of simulation results to the subgroup prevalence.
We predicted that patterns 1 and 3 were more likely to be observed in the phase II trial
according to the historical data.
We assumed the ve clinical scenarios for the simulation study based on hazard ratios
as shown in Table 1. Each scenario is characterized by the true (xed) hazard ratios
(HR1, HR2, HR3, HR4) for the four subgroups. Scenario (1) is a null case, with all
hazard ratios equal to 1.0. The sensitive subpopulation, found under each scenario, is
indicated in boldface. In order to dene the sensitive subpopulation, we rst specify
the ecacy threshold so that subgroup g is contained in the sensitive subpopulation
if HRg  the threshold. One possible way to specify the ecacy threshold may be to
hold discussions with physicians regarding the published results of clinical trials, because
such a specication needs to take into account the current medical environment, such
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as state of the art therapy and medical costs. For example, in advanced HCC, Llovet
et al. [21] explored the ability of several biomarkers to predict the ecacy of a new
small molecule, sorafenib, using the data from the phase III sorafenib HCC assessment
randomized protocol (SHARP) trial [22]. Based on this report as well as other previous
data, we solicited the opinions of the two hepatologists in the study group regarding the
ecacy threshold. They suggested that the ecacy threshold = 0.6 should be clinically
acceptable. We will use a power value to designate the probability of correctly identifying
the target subgroup(s) as the sensitive subpopulation under alternative scenarios, and
a type I error to designate the probability of identifying any subgroup(s) under the null
scenario.
Taking historical data on second-line therapies for HCC into account, for the simu-
lations, we assumed that the median PFS time was 2.8 months for all four subgroups in
the control arm of the trial, with 12.0 months of patient recruitment and 15.0 months
of maximum follow-up (i.e., 3.0 months of minimum follow-up). In addition, we as-
sumed that patients arrived uniformly during the recruitment period. Assuming that
the patient PFS times are i.i.d. Exp(), exponential with parameter , which has pdf
f(t j ) = exp( t), we generated PFS times using the xed parameter c = 0.33 for
the control arm. For the experimental arm, we used the parameter cHRg to generate
PFS times in subgroups g for g = 1; : : : ; 4. The SAS programs to carry out simulations
using the S-A and R-M methods are provided in the Supplementary Materials (SAS for
Windows release 9.3; SAS Institute Inc., Cary, NC, USA).
4.2 Simulation results
In presenting the results of the simulation studies comparing the S-A and R-M methods,
we summarize the probabilities of identifying i) none of the four subgroups, ii) subgroup
4 only, iii) subgroups 3 and 4, iv) subgroups 2 to 4, and v) all four subgroups, as being in
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the sensitive subpopulation; these categories are denoted by Pnone, P4, P3 4, P2 4, and
Pall, respectively. We chose the combination of  = :80,  = .70, and stop = 0.2, which
were judged to provide the best operating characteristics for the two methods, based
on the extensive simulations (as shown in Supplementary Tables in the supplementary
on-line materials). Table 2 shows the simulation results with N = 500 under the ve
clinical scenarios with the ve patterns of patient subpopulation proportions.
Under scenario (1) (null), the R-M method yielded extremely high probabilities of
identifying none of the four groups (Pnone = 0.98 - 1.00), while the values of Pnone with
the S-A method were 0.70 to 0.80. That is, the R-M method suciently controlled type I
error, holding it to less than 0.05 regardless of the pattern of subpopulation proportions
under N = 500, while the S-A method did not. In addition, the R-M method resulted in
early trial termination due to considerably high probabilities of identifying none of the
four groups, especially at the rst interim analysis. The likelihood of early termination
diered signicantly between the R-M and S-A methods. This may be because the R-
A method analyzed the data observed in all four subgroups resulting in much sharper
posterior distributions of g than those obtained by the S-A method that used the data
observed in each subgroup.
Under scenario (2) (linear), neither of the two methods worked suciently well, that
is, P3 4 were at most 0.50 for both methods. In cases where an obvious sensitive sub-
population may not seem to exist, such as in this scenario that assumes that the hazard
ratios change steadily over subgroups, it may be hard to denitively identify the target
subpopulation using either of the methods. Under scenario (3) (step-down), although
both the S-A and R-M methods performed well overall, the performance of the R-M
method may depend signicantly on subpopulation proportions. In pattern 4 in partic-
ular, where the number of patients enrolled in subgroup 1 (non-sensitive subpopulation)
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was very slight, the R-M method was more likely to select all the subgroups resulting in
poorer performance. Under scenario (4) (very high ecacy in subgroups 3 and 4), the
R-M method selected subgroups 3 and 4 at suciently high probabilities across all pat-
terns of subpopulation proportions and these probabilities were higher than or almost
equal to those obtained by the S-A method. Under scenario (5) (very high ecacy only
in subgroup 4), the two methods were almost comparable in terms of the probability of
identifying subgroup 4 under pattern 1. In cases where the subpopulation proportion of
subgroup 4 (sensitive subpopulation) was relatively high, such as in patterns 2 and 4,
the R-M method performed much better than the S-A method, as expected. However,
under patterns 3 and 5, in which the subpopulation proportion of subgroup 4 was small,
the performance of the R-M method was lower than that of the S-A method.
Figure 1 indicates the type I error rates (lower circles) and power values (upper
circles) provided by the R-M method for the six sample sizes (N = 250, 300, 350,
400, 450, 500) under the ve patterns of subpopulation proportions. In this simulation
study, we focused only on the R-M method because the S-A method could not suciently
control the type I error rate even under N = 500. The R-M method held the type I error
to less than 0.05 even under N = 250. In terms of providing 80% of the power, N = 300
may be sucient for the projected total sample size of the phase II trial, considering
that we actually expect the subpopulation proportions to be like pattern 1 or 3.
5. DISCUSSION
We have proposed a Bayesian approach with two alternative methods to identify a
sensitive subpopulation in the setting of a randomized phase II clinical trial. Taking the
simulation results into account, the R-M method may be recommended as the primary
choice. The limitations of our proposed approach include: (a) the requirement of a large
sample size for a phase II trial, (b) the inadequate study monitoring, (c) the monotonicity
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assumption for hazard ratios of PFS for biomarker subgroups, (d) the requirement that
a specic quantitative biomarker for sensitivity be established in advance, and (e) lack
of experience using our proposed method in an actual clinical trial.
Considering the feasibility of patient enrollment, the projected sample size N = 300
may be the upper limit in a clinical trial of second-line therapies for HCC. N = 300
may be achievable by enrolling, for instance, 25 patients per month for one year in a
multi-national trial setting. In some cases, however, it may be unrealistic to enroll such a
large number of patients into a phase II trial due to the associated development costs. If
we can successfully identify a sensitive subpopulation, however, the required sample size
might be minimized in a subsequent phase III trial of an enriched patient population,
thereby optimizing the total sample size for the entire clinical development of a new
agent. In the phase II trial design, we considered early termination of the entire trial
only. Because the trial is still in phase II, it may be highly recommended to monitor the
safety of the new treatment. For example, a safety criterion to monitor the probability
of toxicity in each subgroup, such as p(prob(Tox)g > 

Tox j D) > stop;Tox, where Tox
represents an acceptable toxicity level, may be useful. In addition, the ecacy and
futility rules for stopping subgroups that we mentioned in Section 3.3 may help reduce
the expected sample size of the phase II trial. This should be evaluated in future works.
Our study design was based completely on a monotonic change in treatment ecacy for
biomarker subgroups. However, such a monotonicity assumption does not necessarily
work in all cases. If data observed in the phase II trial indicates a non-monotonic change,
such as \V-shape", the S-A method modied to select the subgroup with the highest
value of p(g < 
 j Dg) may work better than the R-M method. Otherwise, we may
need to develop an alternative method based on an isotonic regression model with the
pool-adjacent-violator algorithm (PAVA) [23].
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In this paper, we focused on identifying a sensitive subpopulation of patients in a
randomized phase II trial to develop a new molecular-targeted anticancer agent. It may
be useful to incorporate our proposed approach into a seamless phase II/III study design
in order to maximize the probability of its successful development, an issue that will be
examined in future works.
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Table I. Patient subgroup population proportions  = f1; 2; 3; 4g and clini-
cal scenarios characterized by the true (xed) hazard ratios fHR1;HR2;HR3;HR4g for
subgroups 1 to 4 for the simulation study. The hazard ratio values in the sensitive
subpopulation under each scenario are indicated in bold-face.
Subgroup
1 2 3 4
Subpopulation
proportion patterns 1 2 3 4
1 Equal 0.25 0.25 0.25 0.25
2 Higher in subgroups 1 & 4 0.35 0.15 0.15 0.35
3 Higher in subgroups 2 & 3 0.15 0.35 0.35 0.15
4 Increasing 0.05 0.15 0.30 0.50
5 Decreasing 0.50 0.30 0.15 0.05
Clinical scenarios HR1 HR2 HR3 HR4
(1) Null case 1.0 1.0 1.0 1.0
(2) Linear 1.0 0.8 0.6 0.4
(3) Step-down 1.0 0.6 0.6 0.35
(4) High ecacy in subgroups 3 & 4 1.0 1.0 0.5 0.3
(5) High ecacy only in subgroup 4 1.0 1.0 1.0 0.5
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Table II. Probabilities of a sensitive subpopulation nding with the xed upper limit
 = .80 and the upper and lower probability cutos  = .70 and stop = .20 when
the total sample size N = 500. The probabilities of identifying i) none of the four
subgroups, ii) subgroup 4 only, iii) subgroups 3 and 4, iv) subgroups 2 to 4, v) all the
four subgroups, are shown in Pnone, P4, P3 4, P2 4, Pall, respectively. The probabilities
of early stopping at the rst and second interim analyses, which are included in Pnone,
are also separately shown. The probability values of correct identication are indicated
in bold face.
Early stopping
Scenario Pattern Method 1st 2nd Pnone P4 P3 4 P2 4 Pall
(1) 1 S-A 0.04 0.05 0.80 0.04 0.05 0.05 0.05
R-M 0.62 0.18 0.99 0.00 0.00 0.00 0.00
2 S-A 0.04 0.04 0.78 0.03 0.08 0.09 0.03
R-M 0.64 0.17 0.99 0.00 0.00 0.00 0.00
3 S-A 0.04 0.04 0.77 0.08 0.03 0.03 0.09
R-M 0.60 0.19 0.99 0.00 0.00 0.00 0.00
4 S-A 0.03 0.03 0.72 0.01 0.04 0.07 0.17
R-M 0.66 0.16 1.00 0.00 0.00 0.00 0.00
5 S-A 0.03 0.03 0.70 0.15 0.09 0.04 0.02
R-M 0.54 0.21 0.98 0.01 0.00 0.00 0.00
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Table II (continued). Simulation results under scenarios (2) and (3).
Early stopping
Scenario Pattern Method 1st 2nd Pnone P4 P3 4 P2 4 Pall
(2) 1 S-A 0.00 0.00 0.00 0.13 0.54 0.28 0.05
R-M 0.00 0.00 0.01 0.15 0.51 0.23 0.10
2 S-A 0.00 0.00 0.00 0.19 0.48 0.30 0.03
R-M 0.00 0.00 0.00 0.24 0.49 0.23 0.04
3 S-A 0.00 0.00 0.00 0.08 0.55 0.28 0.09
R-M 0.01 0.00 0.02 0.09 0.49 0.22 0.18
4 S-A 0.00 0.00 0.00 0.09 0.50 0.25 0.17
R-M 0.00 0.00 0.00 0.11 0.38 0.16 0.34
5 S-A 0.00 0.00 0.04 0.15 0.49 0.30 0.02
R-M 0.06 0.02 0.17 0.16 0.41 0.23 0.03
(3) 1 S-A 0.00 0.00 0.00 0.04 0.15 0.76 0.05
R-M 0.00 0.00 0.00 0.06 0.09 0.71 0.15
2 S-A 0.00 0.00 0.00 0.09 0.21 0.68 0.03
R-M 0.00 0.00 0.00 0.13 0.16 0.64 0.07
3 S-A 0.00 0.00 0.00 0.01 0.11 0.79 0.09
R-M 0.00 0.00 0.00 0.03 0.05 0.62 0.31
4 S-A 0.00 0.00 0.00 0.04 0.20 0.59 0.17
R-M 0.00 0.00 0.00 0.05 0.07 0.33 0.55
5 S-A 0.00 0.00 0.00 0.04 0.11 0.83 0.02
R-M 0.02 0.00 0.04 0.05 0.07 0.80 0.04
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Table II (continued). Simulation results under scenarios (4) and (5).
Early stopping
Scenario Pattern Method 1st 2nd Pnone P4 P3 4 P2 4 Pall
(4) 1 S-A 0.00 0.00 0.00 0.04 0.86 0.06 0.05
R-M 0.00 0.00 0.00 0.04 0.92 0.02 0.02
2 S-A 0.00 0.00 0.00 0.11 0.78 0.09 0.03
R-M 0.00 0.00 0.00 0.13 0.82 0.03 0.02
3 S-A 0.00 0.00 0.00 0.01 0.87 0.03 0.09
R-M 0.00 0.00 0.00 0.01 0.96 0.01 0.02
4 S-A 0.00 0.00 0.00 0.02 0.74 0.07 0.17
R-M 0.00 0.00 0.00 0.03 0.81 0.05 0.12
5 S-A 0.00 0.00 0.01 0.10 0.83 0.04 0.02
R-M 0.04 0.01 0.07 0.09 0.82 0.02 0.01
(5) 1 S-A 0.00 0.00 0.04 0.80 0.05 0.05 0.05
R-M 0.07 0.02 0.14 0.82 0.03 0.00 0.01
2 S-A 0.00 0.00 0.01 0.79 0.08 0.09 0.03
R-M 0.03 0.01 0.05 0.87 0.06 0.01 0.01
3 S-A 0.00 0.00 0.10 0.75 0.03 0.03 0.09
R-M 0.16 0.05 0.32 0.66 0.01 0.00 0.01
4 S-A 0.00 0.00 0.00 0.72 0.04 0.07 0.17
R-M 0.01 0.00 0.02 0.94 0.02 0.00 0.02
5 S-A 0.01 0.01 0.29 0.57 0.09 0.04 0.01
R-M 0.29 0.14 0.67 0.31 0.01 0.00 0.00
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Figure Legends
Figure 1. Type I error rates (lower circles) and power values (upper circles) provided
by R-M method for the six sample sizes (N = 250, 300, 350, 400, 450, 500) under the
ve patterns of subpopulation proportions; patterns 1: black, 2: blue, 3: red, 4: green,
5: yellow. In this investigation, the power is evaluated by the probability of correctly
identifying subgroups 3 and 4 under scenario (4). The xed design parameters  = .80,
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